

Haematologica
HAEMATOL/2016/156448
Version 1

Is ruxolitinib a potential useful drug in hematological malignancies with
RAS pathway hyperactivation ?

Klaus Geissler, Eva Jäger, Agnes Barna, Thamer Sliwa, Paul Knöbl,
Ilse Schwarzinger, Heinz Gisslinger, and Peter Valent

Disclosures: KG: Honoraria and research funding (Novartis) EJ: Nothing to disclose AB:
Nothing to disclose TS: Honoraria (Novartis) PK: Nothing to disclose HG: Honoraria and
research funding (Novartis) PV: Honoraria and research funding (Novartis)

Contributions: KG designed the research and performed the statistical analysis EJ and AB
performed the research TS, PK, IS, HG collected data KG and PV analyzed and
interpreted the data KG and PV wrote the manuscript All authors reviewed the draft
manuscript, and approved the final version for submission